{"id":"W2214632401","doi":"10.1200/jco.2006.24.18_suppl.3059","title":"A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; XIAP; Peripheral blood mononuclear cell; Apoptosis; Internal medicine; Gastroenterology; Pharmacology; Programmed cell death; In vitro; Caspase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007029461,0.001162392,0.001252972,0.0002929458,0.0003183192,0.0007063864,0.0005499728,0.0009589791,0.002469491],"category_scores_gemma":[0.0004732005,0.000397921,0.0006559829,0.000306877,0.0007575181,0.0005774639,0.0002781585,0.002671274,0.0005806363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006579267,"about_ca_system_score_gemma":0.001029312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006078366,"about_ca_topic_score_gemma":0.001101628,"domain_scores_codex":[0.9998301,0.00005931179,0.000008574026,0.00003906264,0.00001520681,0.00004766827],"domain_scores_gemma":[0.9996444,0.00005841838,0.00004910757,0.00002635494,0.00001940262,0.0002023088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6421677,0.05585139,0.007982966,0.0009387225,0.0008836025,0.001030867,0.0006660114,0.005795034,0.114008,0.0009090934,0.007177906,0.1625888],"study_design_scores_gemma":[0.4436111,0.5346245,0.009495226,0.00004076123,0.0002051509,0.0005318435,0.00006521856,0.002026912,0.005289035,0.0003048024,0.003774673,0.00003075614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943453,0.001296576,0.0005518387,0.000372569,0.0001166341,0.001274027,0.0004413827,0.0000804233,0.001521302],"genre_scores_gemma":[0.9931565,0.000980902,0.001334433,0.0005141067,0.000103089,0.001083058,0.001102669,0.00001628169,0.00170894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002469491,"threshold_uncertainty_score":0.008261263,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0277350046880505,"score_gpt":0.4094865877177187,"score_spread":0.3817515830296682,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}